SELL Aurobindo Pharma — Emkay Global, 27 Jul 2026

SELLAurobindo Pharma

Aurobindo Pharma share price target & all analyst calls

byEmkay GlobalHorizon: NA (inferred 1 year)27 Jul 2026via ET Now (Live)

Entry₹1,533.5Inferred

Target₹950

Total upside +38.05%

Stop lossNot given

CMP₹1,571.72d ago

Active-2.49%+39.56%upside left 9 mo left

Follow Emkay Global for new calls(64% target hit, 377 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 10 other Long-term calls on AUROPHARMA See 274 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 9:32 pm IST

7 supporting16 neutral50 opposing

Supports the SELL call (7)

1 other SEBI-registered advisor has an active long-term SELL call on this stock

Advisor consensus · same horizon·6 Aug · 3mo ago

Neutral / worth noting (16)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 6d ago

These four pharma stocks will be reacting to important news updates today

NewsCnbc-Tv18·5 Oct · 3w ago

Aurobindo Pharma Ltd has announced the acquisition of a step-down subsidiary located in the USA.

BSE · Company Update·2 Oct · 3w ago

Weighs against the SELL call (50)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·23 Oct · 2d ago

5 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·7 Oct · 3w ago

Aurobindo Pharma Shares in Focus After USFDA Approval for Perampanel

NewsGoogle News·5 Oct · 3w ago

Aurobindo Pharma USFDA Approval Sparks Rally to New 52-Week High

NewsGoogle News·5 Oct · 3w ago

Aurobindo Pharma Gets USFDA Nod for Generic Epilepsy Tablets

NewsGoogle News·5 Oct · 3w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Emkay Global

Every call and its outcome